Engineered T Cells Market Registering a CAGR of 46.5% from 2017 to 2023 – Autolus ,Bellicum Pharmaceuticals,Cell Medica, Elli Lilly, Gilead Sciences, Juno Therapeutics, Novartis, Oxford Biomedica, Pfizer, Precision Bioscience

T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.

Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market. 

Get Sample Copy at: https://www.premiummarketinsights.com/sample/AMR00013682

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on end user assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market. 

Ask for Discount at: https://www.premiummarketinsights.com/discount/AMR00013682

Table of Content:

1 Introduction
1.1 Scope of Study
2 Key Takeaways
3 Engineered T Cells Market Landscape
3.1 Market Overview
3.2 Market Segmentation
3.3 PEST Analysis
4 Engineered T Cells Market- Key Industry Dynamics
4.1 Key Market Drivers
4.2 Key Market Restraints
4.3 Key Market Opportunities
4.4 Future Trends
4.5 Impact Analysis
5 Engineered T Cells Market Analysis- Global
5.1 Global Engineered T Cells Market Overview
5.2 Global Engineered T Cells Market Forecasts and Analysis
5.3 Market Positioning/Market Share
5.4 Performance of Key Players
5.5 Expert Opinions Engineered T Cells Market

 

Get Complete Report at:

https://www.premiummarketinsights.com/buy/AMR00013682

 

Contact Info:
Name: Sameer Joshi
Email: [email protected]
Organization: Premium Market Insights
Phone: +1-646-491-9876

 

About Premium Market Insights:

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

 

Posted by on Wednesday September 11 2019, 4:30 AM EDT. All trademarks acknowledged. Filed under Biotechnology, Business Services, Diagnostics, Featured Press Release, Healthcare, Life Sciences, Medical Devices, Pharmaceuticals. Comments and Trackbacks are open. Follow responses: RSS 2.0

Leave a Reply

News Categories

Featured Press Releases

Latest News

Log in